B. Metzler seel. Sohn & Co. AG Has $7.06 Million Stock Holdings in Elevance Health, Inc. $ELV

Key Points

• B. Metzler reduced its stake in Elevance Health by 20.5% to 21,834 shares, with holdings valued at $7.06 million at the end of the quarter.
• Elevance beat EPS expectations ($3.33 vs. $3.10) while revenue slightly missed but was up 9.6% year‑over‑year; analysts hold a "Moderate Buy" consensus with a $390.55 average price target, and the company raised its quarterly dividend to $1.72 (2.4% yield; ex‑dividend Mar 10).

B. Metzler seel. Sohn & Co. AG reduced its stake in Elevance Health, Inc. (NYSE:ELV - Free Report) by 20.5% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 21,834 shares of the company's stock after selling 5,643 shares during the quarter. B. Metzler seel. Sohn & Co. AG's holdings in Elevance Health were worth $7,055,000 at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in the stock. Physician Wealth Advisors Inc. boosted its position in shares of Elevance Health by 331.6% during the 3rd quarter. Physician Wealth Advisors Inc. now owns 82 shares of the company's stock valued at $26,000 after purchasing an additional 63 shares in the last quarter. Activest Wealth Management boosted its holdings in shares of Elevance Health by 66.7% during the 3rd quarter. Activest Wealth Management now owns 85 shares of the company's stock worth $27,000 after buying an additional 34 shares in the last quarter. Rossby Financial LCC boosted its holdings in shares of Elevance Health by 110.0% during the 3rd quarter. Rossby Financial LCC now owns 84 shares of the company's stock worth $28,000 after buying an additional 44 shares in the last quarter. Vermillion & White Wealth Management Group LLC grew its position in shares of Elevance Health by 94.9% during the 2nd quarter. Vermillion & White Wealth Management Group LLC now owns 76 shares of the company's stock worth $30,000 after buying an additional 37 shares during the period. Finally, BOK Financial Private Wealth Inc. acquired a new stake in shares of Elevance Health during the 2nd quarter worth approximately $32,000. 89.24% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of research firms have recently issued reports on ELV. Wells Fargo & Company cut their price objective on shares of Elevance Health from $424.00 to $391.00 and set an "overweight" rating on the stock in a research report on Friday, January 30th. Mizuho set a $413.00 target price on Elevance Health in a research report on Friday, January 9th. Leerink Partners upped their price target on Elevance Health from $350.00 to $357.00 and gave the stock a "market perform" rating in a research note on Thursday, January 29th. Wolfe Research set a $425.00 price target on Elevance Health and gave the stock an "outperform" rating in a report on Thursday, January 8th. Finally, Royal Bank Of Canada cut Elevance Health from an "outperform" rating to a "sector perform" rating and set a $358.00 price objective for the company. in a research note on Tuesday, February 3rd. Twelve investment analysts have rated the stock with a Buy rating, nine have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Elevance Health has a consensus rating of "Moderate Buy" and a consensus price target of $390.55.

Elevance Health Stock Up 1.1%

Elevance Health stock opened at $289.56 on Monday. The firm has a 50 day moving average price of $344.64 and a 200-day moving average price of $335.34. The company has a quick ratio of 1.54, a current ratio of 1.54 and a debt-to-equity ratio of 0.70. Elevance Health, Inc. has a twelve month low of $273.71 and a twelve month high of $458.75. The company has a market capitalization of $63.91 billion, a P/E ratio of 11.53, a P/E/G ratio of 1.60 and a beta of 0.51.

Elevance Health (NYSE:ELV - Get Free Report) last posted its quarterly earnings results on Wednesday, January 28th. The company reported $3.33 EPS for the quarter, topping analysts' consensus estimates of $3.10 by $0.23. The company had revenue of $49.31 billion for the quarter, compared to analysts' expectations of $49.52 billion. Elevance Health had a net margin of 2.84% and a return on equity of 15.59%. Elevance Health's revenue was up 9.6% on a year-over-year basis. During the same quarter in the previous year, the firm posted $3.84 EPS. Elevance Health has set its FY 2026 guidance at 25.500- EPS. As a group, equities analysts predict that Elevance Health, Inc. will post 33.96 EPS for the current year.

Elevance Health Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, March 25th. Investors of record on Tuesday, March 10th will be paid a $1.72 dividend. The ex-dividend date is Tuesday, March 10th. This represents a $6.88 dividend on an annualized basis and a yield of 2.4%. This is an increase from Elevance Health's previous quarterly dividend of $1.71. Elevance Health's dividend payout ratio (DPR) is presently 27.23%.

Elevance Health Profile

Elevance Health, Inc NYSE: ELV is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company's strategic focus on integrated health care and benefit delivery.

Elevance's core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.